Otonomy (NASDAQ: OTIC) is one of 305 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Otonomy to similar companies based on the strength of its earnings, profitability, risk, institutional ownership, analyst recommendations, valuation and dividends.
Volatility and Risk
Otonomy has a beta of 2.81, suggesting that its share price is 181% more volatile than the S&P 500. Comparatively, Otonomy’s competitors have a beta of 6.54, suggesting that their average share price is 554% more volatile than the S&P 500.
This is a breakdown of recent recommendations for Otonomy and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Otonomy currently has a consensus price target of $10.00, indicating a potential upside of 233.33%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.01%. Given Otonomy’s higher possible upside, research analysts clearly believe Otonomy is more favorable than its competitors.
Valuation and Earnings
This table compares Otonomy and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Otonomy Competitors||$290.00 million||$35.57 million||165.93|
Otonomy’s competitors have higher revenue and earnings than Otonomy. Otonomy is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
88.8% of Otonomy shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 12.7% of Otonomy shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Otonomy and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Otonomy competitors beat Otonomy on 9 of the 12 factors compared.
Otonomy Company Profile
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
What are top analysts saying about Otonomy Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Otonomy Inc. and related companies.